AVANT To Present At Rodman & Renshaw 8th Annual Healthcare Conference.NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Dr. Una S. Ryan, President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the Rodman rod·man n. One who carries and employs a leveling rod under the supervision of a surveyor. & Renshaw 8th Annual Healthcare Conference on Tuesday, November 7th at 3:10 p.m., ET. The conference is being held November 6-8, 2006 in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. at the New York Palace
A live audio webcast of the presentation will be available online via the Investor Information area of AVANT's web site at http://www.avantimmune.com or via the conference-sponsored website at http://www.wsw.com/webcast/rrshq10/avan/. An archive of the webcast will be available on both sites for 90 days following the event. A conference agenda is posted on the Rodman & Renshaw web site at www.rodmanandrenshaw.com. AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. that harness the human immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to prevent and treat disease. AVANT has three products on the market and five of AVANT's products are in clinical development, including a treatment to reduce complement-mediated tissue damage associated with cardiac bypass surgery Bypass surgery A surgical procedure that grafts blood vessels onto arteries to reroute the blood flow around blockages in the arteries (arteriosclerosis). and a novel vaccine for cholesterol management. AVANT is also developing a pipeline of bacteria-fighting products for biodefense, travelers' vaccines, and global health needs based on AVANT'S rapid-protecting, single-dose, oral and temperature stable vaccine technology. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion